Lenzetto

Estradiol, the active ingredient in Lenzetto, is an estrogen presented as a transdermal patch for transdermal use. It restores estrogenic activity in target tissues and is indicated for the relief of menopausal symptoms and treatment of estrogen deficiency in adult women. The patch delivers estradiol systemically, providing a steady hormone level that can alleviate vasomotor symptoms, urogenital atrophy, and bone loss associated with menopause. It is prescribed by healthcare professionals after evaluating individual risk factors and contraindications and patient preferences.

GNH USA supplies Lenzetto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lenzetto (estradiol) is used in hormone replacement therapy to address estrogen deficiency. - Menopausal symptoms: alleviates hot flashes, night sweats, and vaginal dryness. - Estrogen deficiency: restores systemic estrogen levels in post‑menopausal women. - Osteoporosis prevention: helps maintain bone mineral density in women with low estrogen.

Common Side Effects: - Skin irritation at application site: redness or itching where the patch is placed. - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Breast tenderness: mild swelling or discomfort.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Stroke: cerebrovascular accident. - Severe allergic reaction: rash, swelling, or difficulty breathing.

Before using Lenzetto, consider the following precautions: - Cardiovascular risk assessment: evaluate history of clotting disorders. - History of thromboembolism: avoid if previous events occurred. - Liver function monitoring: check hepatic enzymes periodically. - Use lowest effective dose: minimize exposure while achieving symptom control. - Contraindication in estrogen‑sensitive cancers: do not use in known breast or endometrial carcinoma. - Store at room temperature: keep patch in original foil pouch, protect from moisture and heat.

Lenzetto may interact with several medicines. Major Interactions (Avoid): - Combined oral contraceptives: increased risk of thromboembolism. - Anticoagulants (e.g., warfarin): may alter anticoagulant effect. - Certain antiepileptics (e.g., carbamazepine): reduce estradiol plasma levels. Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase estradiol exposure. - CYP3A4 inducers (e.g., rifampin): may decrease estradiol exposure.